Drug Profile
Drospirenone/estradiol/prasterone - ANI Pharmaceuticals/Pantarhei Bioscience
Alternative Names: Androgen Restored Contraceptive; ARC; Female balance pill - ANI Pharmaceuticals/Pantarhei Bioscience; Pill-Plus; Triple OCLatest Information Update: 02 Oct 2021
Price :
$50
*
At a glance
- Originator BioSante Pharmaceuticals
- Developer Pantarhei Bioscience
- Class Androstenes; Androstenols; Antiandrogens; Estradiol congeners; Estrenes; Hormonal contraceptives; Hormonal replacements; Progesterone congeners; Small molecules
- Mechanism of Action Dehydroepiandrosterone replacements; Estrogen receptor agonists; Progesterone receptor agonists
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity No
- Available For Licensing Yes
Highest Development Phases
- Phase III Female sexual dysfunction; Pregnancy
Most Recent Events
- 03 Sep 2021 Drospirenone/estradiol/prasterone - ANI Pharmaceuticals/Pantarhei Bioscience is available for licensing in USA, Asia as of 04 Feb 2019. https://www.pantarheibio.com/pipeline/androgen-restored-contraception/ (Pantarhei Bioscience website, September 2021)
- 31 Aug 2018 Androgen Restored Contraception is still in phase II/III trials for Female sexual dysfunction in Netherlands (Pantarhei Bioscience website, August 2018)
- 31 Aug 2018 Pantarhei Biosciences plans a phase III trial (Pantarhei Bioscience website, August 2018)